2-(tert-butoxycarbonyl)-(3R)-3-isobutylsuccinic acid | 219616-31-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(tert-butoxycarbonyl)-(3R)-3-isobutylsuccinic acid
• 英文别名: 1-tert.butyl dihydrogen 4-methyl-1(RS),1,2(R)-pentanetricarboxylate；(3R)-2-[(2-methylpropan-2-yl)oxycarbonyl]-3-(2-methylpropyl)butanedioic acid
• CAS: 219616-31-6
• 化学式: C₁₃H₂₂O₆
• 分子量: 274.314
• InChiKey: FAXYLEFAVKRBCD-VEDVMXKPSA-N

物化性质

• 沸点：
  377.4±32.0 °C(Predicted)
• 密度：
  1.157±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(tert-butoxycarbonyl)-(3R)-3-isobutylsuccinic acid 在 N-甲基吗啉 作用下， 以 甲苯 为溶剂， 生成 (R)-2-(2-(叔丁氧基)-2-氧代乙基)-4-甲基戊酸
  参考文献：
  名称：

  Design and synthesis of the cartilage protective agent (CPA, Ro32-3555)

  摘要：

  A novel series of MMP inhibitors has been identified. The compounds are potent selective inhibitors of collagenase with good solubility and oral bioavailability. One compound, designated Ro32-3555, has been selected for development as a cartilage protective agent for use in the treatment of rheumatoid-and osteoarthritis. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00416-2
• 作为产物：
  描述：

  benzyl 2R-trifluoromethanesulfonyloxy-4-methylvalerate 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 、 水 为溶剂， 反应 5.0h， 生成 2-(tert-butoxycarbonyl)-(3R)-3-isobutylsuccinic acid
  参考文献：
  名称：

  Synthesis of an Inhibitor-Tethered Resin for Detection of Active Matrix Metalloproteinases Involved in Disease

  摘要：

  Matrix metalloproteinases ( MMPs), of which 26 members are known in humans, are implicated in a number of diseases. Their activity is strictly controlled, but when the biological control over the activity is lost, disease processes set in. In an attempt to delineate what MMP activity has gone awry in what diseases, including metastatic cancers that are of special interest to our laboratories, we conceived and synthesized two chromatographic resins incorporated with a multifunctional broad- spectrum inhibitor for MMPs. The broad-spectrum inhibitor contains three sterogentic centers and was synthesized in 13 steps. Two structural variants of the inhibitors were linked to the polymer support via disulfide moieties. These resins are intended for use in cellular systems to selectively fish out from a complex mixture of all cellular proteins the active MMP forms important for the specific disease for identification.

  DOI：

  10.1021/jo060058h

文献信息

• NOVEL HYDROXAMIC ACID DERIVATIVES
  申请人：Daiichi Fine Chemical Co., Ltd.

  公开号：EP1179529A1

  公开（公告）日：2002-02-13

  Disclosed are compounds which have not only potent metalloproteinase-inhibiting activity but also amazingly excellent bioavailability and biological activity in vivo, including the property of being well absorbed via oral routes, thereby serving as useful pharmaceuticals, intermediates and processes for the production thereof. The disclosed compounds of the formula (I): wherein R1 is hydrogen, or a hydroxy-protecting group; R2 is hydrogen, or an amino-protecting group; R3, R7, and R8, which may be identical or different, are each independently hydrogen, hydroxy, unsubstituted or optionally substituted (C1-C6) alkyl, or unsubstituted or optionally substituted aryl-(C1-C6) alkyl; R4 is unsubstituted or optionally substituted (C1-C6) alkyl, or unsubstituted or optionally substituted aryl-(C1-C6) alkyl; R5 is hydrogen, unsubstituted or optionally substituted alkyl, unsubstituted or optionally substituted aralkyl, or a carboxy-protecting group; R6 is hydrogen, hydroxy, amino, and a group of the formula: -X-Y wherein X is oxygen, (C1-C6) alkylene or phenylene, Y is a group of the formula: -A-B or -B, wherein A is (C1-C6) alkylene, imino, and (C1-C6) alkyleneimino, and B is hydrogen, amino, amidino, sulfonyl, acylimidoyl, unsubstituted or optionally substituted imidazolyl, unprotected or optionally protected bis(phosphono)methyl or unprotected or optionally protected bis(phosphono)hydroxymethyl; or salts thereof are useful for pharmaceutical and/or veterinary compositions, particularly as metalloproteinase inhibitors which inhibit matrix metalloproteinases or tumor necrosis factor-α-converting enzymes (TNF-α convertases).

  本公开的化合物不仅具有强大的金属蛋白酶抑制活性，而且在体内具有出色的生物利用度和生物活性，包括经口途径吸收良好的特性，因此可用作有用的药物、中间体和生产过程。公开的化合物的结构式（I）如下：其中R1是氢或羟基保护基；R2是氢或氨基保护基；R3、R7和R8可以相同也可以不同，分别独立地是氢、羟基、未取代或可选择取代的（C1-C6）烷基，或未取代或可选择取代的芳基-（C1-C6）烷基；R4是未取代或可选择取代的（C1-C6）烷基，或未取代或可选择取代的芳基-（C1-C6）烷基；R5是氢、未取代或可选择取代的烷基、未取代或可选择取代的芳基烷基，或羧基保护基；R6是氢、羟基、氨基，以及下式的基团：-X-Y，其中X是氧、（C1-C6）烷基或苯基，Y是下式的基团：-A-B或-B，其中A是（C1-C6）烷基、亚胺基和（C1-C6）烷基亚胺基，B是氢、氨基、酰胺基、磺酰基、乙酰亚胺基，未取代或可选择取代的咪唑基，未保护或可选择保护的双（膦酸甲基）或未保护或可选择保护的双（膦酸羟甲基）；或其盐在制药和/或兽医组合物中具有用途，尤其作为抑制基质金属蛋白酶或肿瘤坏死因子-α转化酶（TNF-α转化酶）的金属蛋白酶抑制剂。
• Hydrazine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06235787B1

  公开（公告）日：2001-05-22

  Hydrazine derivatives of the formula wherein Y is CO or SO2; R1 is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R2 is lower alkyl, halo-lower alkyl, aryl-lower alkyl, aryl-lower alkenyl or aryl when Y is SO2 and is lower alkyl, halo-lower alkyl, lower alkoxy, lower alkoxycarbonyl, acyl, lower cycloalkyl, aryl, aryl-lower alkyl, aryl-lower alkoxy or NR5R6 when Y is CO; and R3 is hydrogen, lower alkyl optionally substituted by cyano, amino, hydroxy, lower alkoxy, lower alkoxycarbonyl, heterocyclyl or heterocyclylcarbonyl, lower alkenyl, lower alkynyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, aryl-lower alkenyl, aryl or heterocyclyl; or R2 and R3 together form the residue of a 5-, 6- or 7-membered cyclic amide, cyclic imide, cyclic sulphonamide or cyclic urethane group; R4 is lower alkyl, hydroxy-lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a group of the formula X-aryl, X-heteroaryl or —(CH2)1-2—CH═CR7R8; X is a spacer group; R5 and R6 each individually are hydrogen, lower alkyl or aryl-lower alkyl; and R7 and R8 together represent a lower alkylene group in which one methylene group is optionally replaced by a hetero atom; and their pharmaceutically acceptable salts inhibit not only the release of tumour necrosis factor (TNF-&agr;) and transforming growth factor (TGF-&agr;) from cells, but also keratinocyte proliferation. They are useful as medicaments, especially for the treatment of inflammation, fever, hemorrhage, sepsis, rheumatoid arthritis, osteoarthritis, multiple sclerosis or psoriasis.

  该公式的肼衍生物，其中Y为CO或SO2; R1为低碳基，低烯基，低环烷基，低环烷基-低碳基，芳基或芳基-低碳基; 当Y为SO2时，R2为低碳基，卤代低碳基，芳基-低碳基，芳基-低烯基或芳基; 当Y为CO时，R2为低碳基，卤代低碳基，低烷氧基，低烷氧羰基，酰基，低环烷基，芳基，芳基-低碳基，芳基-低烷氧基或NR5R6; R3为氢，低碳基，可选地被氰基，氨基，羟基，低烷氧基，低烷氧羰基，杂环烷基或杂环烷基羰基取代的低碳基，低烯基，低炔基，低环烷基，低环烷基-低碳基，芳基-低碳基，芳基-低烯基，芳基或杂环烷基取代的低碳基; 或R2和R3一起形成5、6或7元环酰胺、环内酰亚胺、环磺酰胺或环脲基的残基; R4为低碳基，羟基-低碳基，低烯基，低环烷基，低环烷基-低碳基或公式X-芳基，X-杂环芳基或—（CH2）1-2—CH═CR7R8的基团; X为间隔基团; R5和R6各自为氢、低碳基或芳基-低碳基; R7和R8一起表示一个低碳亚基，其中一个亚甲基团可选地被杂原子取代; 以及它们的药学上可接受的盐不仅抑制肿瘤坏死因子（TNF-&agr;）和转化生长因子（TGF-&agr;）的释放，而且抑制角质细胞增殖。它们可用作药物，特别是用于治疗炎症，发热，出血，败血症，类风湿性关节炎，骨关节炎，多发性硬化或银屑病。
• NOVEL METALLOPROTEINASE INHIBITORS
  申请人：FUJI YAKUHIN KOGYO KABUSHIKI KAISHA

  公开号：EP1038864A1

  公开（公告）日：2000-09-27

  Compounds having not only a high metalloproteinase inhibitory activity but also remarkably improved medicinal applicability in vivo (oral absorbability, etc.) and biological activities and thus being useful a drugs; intermediates in the process for producing the same; and a process for producing these compounds. Specifically, compounds represented by general formula (I) or salts thereof, useful in medicinal and/or veterinary compositions, in particular; metalloproteinase inhibitors inhibiting matrix metalloproteinases and tumor necrosis factor-α (TNF-α) convertase; wherein R1 represents hydrogen or a hydroxy-protective group; R2 represents hydrogen or an amino-protective group; R3, R7 and R8 represent each hydrogen, hydroxy, alkyl, etc.; R4 represents alkyl, arylalkyl, etc.; R5 and R6 are the same or different and each represents hydrogen, alkyl, cycloalkyl, etc.; and R9 represents hydrogen, hydroxy, amino, etc.

  不仅具有较高的金属蛋白酶抑制活性，而且具有明显改善的体内药用性（口服吸收性等）和生物活性，因而可用作药物的化合物；生产这些化合物的中间体；以及生产这些化合物的工艺。具体地说，通式(I)代表的化合物或其盐，可用于药物和/或兽药组合物，特别是；金属蛋白酶抑制剂，可抑制基质金属蛋白酶和肿瘤坏死因子-α（TNF-α）转化酶；其中 R1 代表氢或羟基保护基团；R2 代表氢或氨基保护基团；R3、R7 和 R8 分别代表氢、羟基、烷基等；R4 代表烷基、氨基保护基团、羟基、烷基等。R4 代表烷基、芳烷基等；R5 和 R6 相同或不同，各自代表氢、烷基、环烷基等；R9 代表氢、羟基、氨基等。
• NOVEL REMEDIES FOR ALLERGIC DISEASES
  申请人：FUJI YAKUHIN KOGYO KABUSHIKI KAISHA

  公开号：EP1101492A1

  公开（公告）日：2001-05-23

  Disclosed are anti-inflammatory agents, antiallergic agents, particularly prophylactically and/or therapeutically effective drugs for type I and/or IV allergic conditions, and further pharmaceutical drugs for prophylactically and/or therapeutically treating bronchial asthma, atopic diseases, etc. The inventive drugs comprising a prophylactically and/or therapeutically effective amount of a hydroxamic acid derivative are active in the prophylaxis and/or therapy of allergy, especially type I and/or IV allergy, etc. The drugs are active in prophylactically and/or therapeutically treating inflammation, rhinitis, conjunctivitis, bronchial asthma, atopic diseases (including dermatitis, enteritis, etc.), or allergic gastroenterocolitis (allergic inflammation in digestive tract). The application of such drugs leads to (A) reduction of cells (such as lymphocytes, neutrophils, mast cells, eosinophils, basophils, macrophages and monocytes) at a diseased site, and/or (B) alleviation of inflammatory symptoms caused by migration, infiltration or accumulation of cells (such as lymphocytes, neutrophils, mast cells, eosinophils, basophils, macrophages and monocytes) to (or at) the diseased site, (C) inhibition of pathophysiological functions in cells (such as lymphocytes, neutrophils, mast cells, eosinophils, basophils, macrophages, monocytes, Langerhans cell and dendritic cells), and/or (D) reducing the blood level or inhibiting the production, of antibodies, especially IgE. Accordingly, the drugs are useful in the prophylaxis and/or therapy of diseases, disorders or ill conditions at the site.

  本发明公开了抗炎剂、抗过敏剂，尤其是对 I 型和/或 IV 型过敏症具有预防和/或治疗效果的药物，以及用于预防和/或治疗支气管哮喘、特应性疾病等的进一步药物。包含预防和/或治疗有效量羟肟酸衍生物的本发明药物在预防和/或治疗过敏症，尤其是 I 型和/或 IV 型过敏症等方面具有活性。这些药物在预防和/或治疗炎症、鼻炎、结膜炎、支气管哮喘、特应性疾病（包括皮炎、肠炎等）或过敏性胃肠炎（消化道过敏性炎症）方面具有活性。使用这类药物可(A)减少患病部位的细胞（如淋巴细胞、中性粒细胞、肥大细胞、嗜酸性粒细胞、嗜碱性粒细胞、巨噬细胞和单核细胞），和/或(B)减轻细胞（如淋巴细胞、中性粒细胞、肥大细胞、嗜酸性粒细胞、嗜碱性粒细胞、巨噬细胞和单核细胞）迁移、浸润或积聚引起的炎症症状、(C) 抑制细胞（如淋巴细胞、中性粒细胞、肥大细胞、嗜酸性粒细胞、嗜碱性粒细胞、巨噬细胞、单核细胞、朗格汉斯细胞和树突状细胞）的病理生理功能，和/或 (D) 降低血液中抗体，尤其是 IgE 的水平或抑制其产生。因此，这些药物可用于预防和/或治疗该部位的疾病、失调或病症。
• HIGHLY WATER-SOLUBLE METALLOPROTEINASE INHIBITOR
  申请人：Daiichi Fine Chemical Co., Ltd.

  公开号：EP0832875B1

  公开（公告）日：2004-06-30